New Endo-UP® Platform, featuring innovative stone management technologies, to be unveiled EDAP’s cutting edge High Intensity Focused Ultrasound (HIFU) and Extracorporeal Shockwave Lithotripsy (ESWL) technologies will also be showcased LYON, France , October 30, 2019 -- EDAP TMS SA
67.8% growth in HIFU revenue through the nine month period ended September 30 over the comparable period in 2018 48.2% Gross margin for the nine month period ended September 30 compared to 42.3% for the comparable period in 2018 Fourth consecutive quarter of profitability Continued to drive US
Farrer Park Hospital becomes the first hospital in Southeast Asia to implement Focal One ® EDAP poised to expand HIFU in Southeast Asia LYON, France , November 26, 2019 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in therapeutic ultrasound, announced today that the first Focal
Study confirms feasibility of using Focal One HIFU to treat rectal endometriosis LYON, France , December 19, 2019 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in therapeutic ultrasound, today announced that Focal One data has been accepted for publication in the journal of
Recaps significant progress made in 2019 and previews expectations for accelerating global growth in 2020 LYON, France , January 9, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in Robotic Energy-based Therapies, today issued the following letter to shareholders: To my
University of Miami Sylvester Comprehensive Cancer Center , a Long-Time EDAP Ablatherm® User, to Upgrade to the Most Advanced HIFU Technology for the Treatment of Prostate Disease Focal One Successfully Launched with Several Patients Treated to Date LYON, France , January 29, 2020 – EDAP TMS SA
LYON, France , February 18, 2020 – EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company recently showcased its Focal One high intensity focused ultrasound (HIFU) device at the 12 th International Symposium on Focal Therapy
LYON, France , March 17, 2020 – EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today issued the following letter to shareholders: To my fellow shareholders, The COVID-19 virus represents a new challenge for us all, and I want to formally update
Company to host conference call and webcast on Tuesday, March 31 st @ 8:30 am EDT LYON, France , March 24, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and year ended
Record full year 2019 revenues of €44.9 million, representing 14.6% year-over-year growth HIFU full year 2019 revenue growth of 28% driven by 54% growth in US installed base Record 46.8% gross profit margin driven by HIFU growth Profitable for the full year 2019 with operating income of €2.2
